At Venture Medical Weight Loss, advanced weight loss injections enhance your weight loss journey by targeting key factors that contribute to effective fat burning and overall weight management
Medical Disclaimer This content is for educational purposes only and is not intended as medical advice, diagnosis, or treatment
In a new study reported in The Lancet, Tirzepatide, a GLP-1R/GIPR agonist, reduced alcohol's rewarding properties, locomotor stimulation, conditioned place preference, and accumbal dopamine release
For BMI 40+, or BMI 35+ with diabetes/sleep apnea, surgery generally produces more durable results
When interpreting our results, it is important to highlight that GLP-1RAs were associated with a reduced incidence of anxiety disorders, autism, bulimia nervosa, PTSD, and schizophrenia